ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00262574
Recruitment Status : Unknown
Verified December 2010 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was:  Recruiting
First Posted : December 7, 2005
Last Update Posted : August 9, 2011
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya

Brief Summary:
Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis that endothelial function will be better in the BNP treated patients compared to the NTG treated patients

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Nesiritide, Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1
Study Start Date : July 2005
Estimated Primary Completion Date : April 2012
Estimated Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angioplasty
Drug Information available for: Nesiritide
U.S. FDA Resources


Intervention Details:
    Drug: Nesiritide,
    PCI


Primary Outcome Measures :
  1. FMD [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:coronary artery disease -

Exclusion Criteria:CHF and/or reduced LV function, or renal failure with Creatinine >2mg%


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262574


Contacts
Contact: Yonathan Hasin, prof. 97246652649 yhasin@poria.health.gov.il
Contact: Diab gahnim, Dr

Locations
Israel
The Baruch Pade medical center, Poriya Recruiting
Tiberias, Israel, 15208
Principal Investigator: Yonathan Hasin, Profesor         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Investigators
Principal Investigator: Mina Arinos Ministry of Health, Israel

Responsible Party: prof yonathan hasin, Israell health ministry
ClinicalTrials.gov Identifier: NCT00262574     History of Changes
Other Study ID Numbers: 20020474-Hasin-BNP.CTIL
First Posted: December 7, 2005    Key Record Dates
Last Update Posted: August 9, 2011
Last Verified: December 2010

Keywords provided by The Baruch Padeh Medical Center, Poriya:
endothelial disfunction
BNP
PCI
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Natriuretic Peptide, Brain
Natriuretic Agents
Physiological Effects of Drugs